Shibu Varughese, MD
Internal Medicine · Marrero, LANPI 1346475506
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.9%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Pfizer accounts for 62.0% of it on its own, with 49 other manufacturers making up the rest. Reporting peaked in 2019 at $5,645 and has fallen 89.2% since, to $611 in 2025. Among internal medicine clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 265 payments — averaging $48.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$8K
- AstraZeneca$492
- Novartis$477
- Novo Nordisk$451
- E.r. Squibb & Sons, L.L.C.$357
- GSK$342
- plus $3K from 44 others
Across 14 payments — averaging $59,608 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$781K
- Eli Lilly$28K
- AstraZeneca$26K
What the payments were for
- Consulting fees$2502%
- Speaking & faculty fees$7,65060%
- Food & beverage$4,78637%
- Education$801%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELIQUIS$7,900
How this compares
$12,766 in reported general payments places this provider in the 95th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 17 | $259,343 |
| EliquisApixaban | 131 | $125,653 |
| OzempicSemaglutide | 68 | $87,723 |
| MounjaroTirzepatide | 61 | $79,610 |
| ZarxioFilgrastim-Sndz | 28 | $47,855 |
| XareltoRivaroxaban | 26 | $28,020 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $27,045 |
| LinzessLinaclotide | 32 | $26,909 |
| JardianceEmpagliflozin | 23 | $24,123 |
| JanuviaSitagliptin Phosphate | 26 | $23,185 |
| FarxigaDapagliflozin Propanediol | 17 | $15,720 |
| ValacyclovirValacyclovir Hcl | 384 | $15,487 |
| TradjentaLinagliptin | 17 | $15,047 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $8,153 |
| Humalog Kwikpen U-200Insulin Lispro | 12 | $6,293 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $19 | $259,34317 claims |
| PfizerEliquis | $7,913 | $125,653131 claims |
| Novo NordiskOzempic | $451 | $87,72368 claims |
| Lilly USA, LLCMounjaro | $153 | $79,61061 claims |
| Boehringer IngelheimJardiance, Tradjenta | $169 | $39,17040 claims |
| Johnson & JohnsonXarelto | $218 | $28,02026 claims |
| GSKTrelegy Ellipta | $342 | $27,04536 claims |
| MerckJanuvia | $117 | $23,18526 claims |
| AstraZenecaFarxiga, Symbicort | $492 | $19,83735 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Marrero
- Amanda FontenotMarrero$142K
- Alan BowersMarrero$20K
- Hong NguyenMarrero$15K
- Donna RyanBaton Rouge$991K
- Steven DeitelzweigNew Orleans$939K
- Bruce SamuelsCovington$200K
- John SchwabBaton Rouge$122K
- Daniel EnglertNew Orleans$74K
- Everett BrownGretna$71K
- Rajan KhannaShreveport$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.